Comments
Dr. Reddy's Laboratories Ltd has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (Gilead) on Remdesivir.
As part of the agreement Gilead will grant Dr. Reddy’s the right to register, manufacture and sell Gilead’s investigational drug, Remdesivir, a potential treatment for Covid-19, in 127 countries including India.
Hyderabad -based Dr Reddy’s will receive technology transfer from Gilead for manufacturing of this drug. Dr. Reddy’s would need to do the manufacturing scale up and obtain regulatory approval for marketing of this drug in respective countries, according to a release.
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (USFDA) to treat Covid-19.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.